Recent Finacing
Recent Raise
Arvinas develops orally available PROTAC small‑molecule degraders that induce targeted intracellular protein degradation to treat oncology and other diseases, advancing AR- and ER-targeting candidates toward clinical trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
